Last reviewed · How we verify
Apidra® SoloStar®
At a glance
| Generic name | Apidra® SoloStar® |
|---|---|
| Also known as | insulin glulisine |
| Sponsor | Geropharm |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Insulin Glulisine (GP40321) Compared to Insulin Glulisine (Apidra® SoloStar®) in Type 1 Diabetes Mellitus Patients (PHASE3)
- A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus (PHASE1)
- Comparison on Efficacy and Safety of Three Inpatient Insulin Therapy in Type2 DM (NA)
- Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients (PHASE3)
- Better Acceptance of Single Injection Apidra Added to Once Daily Lantus Versus Twice Daily Premixed Insulin in Real Life Use Setting (PHASE4)
- Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients (PHASE4)
- Insulin Glargine for Diabetes Metabolism(DM)Type II Patients Under Enteral Nutrition (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Apidra® SoloStar® CI brief — competitive landscape report
- Apidra® SoloStar® updates RSS · CI watch RSS
- Geropharm portfolio CI